Investment analysts at Deutsche Bank initiated coverage on shares of CVS Health (NYSE:CVS) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $90.00 price target on the pharmacy operator’s stock. Deutsche Bank’s price objective points to a potential upside of 25.54% from the stock’s current price.

A number of other research firms also recently commented on CVS. Wolfe Research downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $89.00 to $82.00 in a report on Monday, August 14th. Robert W. Baird reiterated an “outperform” rating and issued a $90.00 price objective on shares of CVS Health in a report on Monday, August 14th. Citigroup cut their price objective on shares of CVS Health from $88.00 to $87.00 and set a “neutral” rating for the company in a report on Thursday, August 17th. Loop Capital started coverage on shares of CVS Health in a report on Thursday, August 24th. They issued a “hold” rating and a $83.00 price objective for the company. Finally, BidaskClub downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a report on Friday, August 25th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $86.35.

CVS Health (CVS) traded down $3.43 on Monday, hitting $71.69. 40,462,409 shares of the company traded hands, compared to its average volume of 6,844,018. CVS Health has a 52-week low of $66.45 and a 52-week high of $84.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The firm has a market cap of $72,620.00, a P/E ratio of 13.16, a PEG ratio of 1.29 and a beta of 0.89.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same quarter in the prior year, the firm earned $1.64 EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. sell-side analysts expect that CVS Health will post 5.9 earnings per share for the current year.

In other CVS Health news, COO Jonathan C. Roberts sold 85,743 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the sale, the chief operating officer now directly owns 119,555 shares in the company, valued at approximately $9,939,802.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Thomas M. Moriarty sold 20,547 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the completion of the sale, the executive vice president now owns 43,178 shares in the company, valued at $3,504,758.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 714,125 shares of company stock worth $58,119,381. 0.61% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in CVS. Pathstone Family Office LLC raised its stake in CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after acquiring an additional 982 shares in the last quarter. Wealthcare Advisory Partners LLC raised its stake in CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares in the last quarter. Fieldpoint Private Securities LLC grew its position in CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the last quarter. Finally, TB Alternative Assets Ltd. purchased a new position in CVS Health during the 2nd quarter worth $121,000. Institutional investors and hedge funds own 82.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/04/deutsche-bank-initiates-coverage-on-cvs-health-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.